Trial Profile
A Multi Center, Multi National, Open Label, Extension Study to Evaluate the Long-term Efficacy and Safety of BMN 044 (PRO044) in Subjects With Duchenne Muscular Dystrophy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs BMN 044 (Primary) ; BMN 044
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 21 Jul 2016 New trial record